NASDAQ:AVXL
Anavex Life Sciences Corp. Stock News
$3.39
-0.0200 (-0.587%)
At Close: Apr 25, 2024
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade
11:26am, Monday, 15'th May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
07:30am, Tuesday, 02'nd May 2023
Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
07:30am, Tuesday, 25'th Apr 2023
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
07:00am, Monday, 10'th Apr 2023
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Buy Anavex For Its Likely Positive Alzheimer's Disease Data
04:06am, Thursday, 16'th Mar 2023
The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a 'spin'.
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing Well
08:50am, Wednesday, 08'th Mar 2023
Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data.
Why Shares of Anavex Life Sciences Rose 12.4% in February
08:21pm, Monday, 06'th Mar 2023
Anavex is a clinical-stage biotech stock with no revenue. The company's lead therapy is being tested to treat a host of neurodegenerative and neurological conditions.
Is Anavex Life Sciences Stock a Buy Now?
03:00pm, Thursday, 23'rd Feb 2023 The Motley Fool
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
Is Anavex Life Sciences Stock a Buy Now?
10:00am, Thursday, 23'rd Feb 2023
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 270.28% as Wall Street Analysts Expect?
02:55pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
01:45pm, Thursday, 09'th Feb 2023 The Motley Fool
Short-sellers have piled into this clinical-stage biopharma stock.
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
08:45am, Thursday, 09'th Feb 2023
Short-sellers have piled into this clinical-stage biopharma stock.
Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDA
08:00am, Thursday, 09'th Feb 2023
Anavex Life Sciences recently reported their Q1 2023 earnings that revealed a beat on EPS and a robust cash position that should fund the company for the next four years. The company updated investors
Why Anavex Life Sciences Stock Bolted Higher in January
03:16pm, Wednesday, 08'th Feb 2023 The Motley Fool
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
Why Anavex Life Sciences Stock Bolted Higher in January
10:16am, Wednesday, 08'th Feb 2023
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
